ArticleTuberculosis and respiratory diseases2025
Management of Chronic Obstructive Pulmonary Disease in Vietnam during the COVID-19 Period: Current Situation and Challenges.
Article in Tuberculosis and respiratory diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cough Assessment in Chronic Respiratory Diseases (COASESS): Findings from a Prospective Multicenter Cross-Sectional Study.Tuberculosis and respiratory diseases · 2026Article
- Response to Daungsupawong et al.Tuberculosis and respiratory diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the alterations in exacerbation rates, other clinical outcomes, and to identify persistent challenges in the management of chronic obstructive pulmonary disease (COPD) in Vietnamese COPD management units (CMUs).
methodsA multi-center, prospective cohort study was conducted on COPD within the CMUs of three study sites. The primary endpoint was exacerbation frequency. Data on demographic and clinical characteristics were collected at the initiation of the study. Participants were followed for 12 to 15 months after enrollment.
resultsThroughout the follow-up period, a decrease was noted in the prevalence of patients requiring hospitalization (from 42.3% to 34.4%) and intensive care unit/emergency department admissions (from 5.7% to 0.6%). The annual rates of exacerbation and hospitalization were 0.75±0.89 and 0.56±0.70, respectively. Factors such as symptom severity, degree of airflow obstruction, and body mass index were associated with increased exacerbation frequency and elevated annual exacerbation rates. Our findings underscore the complexities and obstacles encountered in managing COPD during the coronavirus disease 2019 (COVID-19) pandemic, including the rise in smoking prevalence, inadequate testing rates, and non-compliance with established treatment guidelines.
conclusionOur study elucidates the challenges and difficulties in managing COPD amidst the COVID-19 pandemic, highlighting issues such as increased smoking rates, insufficient testing, and deviations from established therapeutic guidelines. These insights lay the groundwork for future intervention strategies and policy enhancements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.